Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2018 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
Fei F, Lim M, Schmidhuber S, Moll J, Groffen J, Heisterkamp N. Fei F, et al. Mol Cancer. 2012 Jun 21;11:42. doi: 10.1186/1476-4598-11-42. Mol Cancer. 2012. PMID: 22721004 Free PMC article.
BACKGROUND: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I mutation in Bcr/Ab …
BACKGROUND: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically appr …
A Pediatric Case of Treatment-related Myelodysplastic Syndrome While on Therapy for Pre-B Acute Lymphoblastic Leukemia.
McElroy S, Myers GD, Flatt T. McElroy S, et al. J Pediatr Hematol Oncol. 2023 May 1;45(4):e518-e521. doi: 10.1097/MPH.0000000000002613. Epub 2023 Jan 10. J Pediatr Hematol Oncol. 2023. PMID: 36706304
BACKGROUND: Treatment-related myelodysplastic syndrome (t-MDS) is a rare late effect of cancer therapy. After alkylating agents, this typically occurs years after completion of therapy. ...OBSERVATIONS: This case demonstrates t-MDS developing in a patient receiving …
BACKGROUND: Treatment-related myelodysplastic syndrome (t-MDS) is a rare late effect of cancer therapy. After alkylating agents, this …
Induction of a central memory and stem cell memory phenotype in functionally active CD4(+) and CD8(+) CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19(+) acute lymphoblastic leukemia.
Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, Assenmacher M, Döring M, Feucht J, Feuchtinger T. Blaeschke F, et al. Cancer Immunol Immunother. 2018 Jul;67(7):1053-1066. doi: 10.1007/s00262-018-2155-7. Epub 2018 Mar 31. Cancer Immunol Immunother. 2018. PMID: 29605883 Free PMC article.
Relapsed/refractory B-precursor acute lymphoblastic leukemia (pre-B ALL) remains a major therapeutic challenge. ...Therefore, we set up a protocol for anti-CD19 CAR T-cell generation aiming at high Tcm/Tscm numbers. 100 ml peripher …
Relapsed/refractory B-precursor acute lymphoblastic leukemia (pre-B ALL) remains a major therap …
Detection of fetomaternal genotype associations in early-onset disorders: evaluation of different methods and their application to childhood leukemia.
Healy J, Bourgey M, Richer C, Sinnett D, Roy-Gagnon MH. Healy J, et al. J Biomed Biotechnol. 2010;2010:369534. doi: 10.1155/2010/369534. Epub 2010 Jun 9. J Biomed Biotechnol. 2010. PMID: 20617153 Free PMC article.
Using this approach, we examined fetomaternal associations between 29 SNPs in 12 cell-cycle genes and childhood pre-B acute lymphoblastic leukemia (ALL). We identified putative fetomaternal effects at loci CDKN2A rs36228834 (P = .017) and CDKN2B …
Using this approach, we examined fetomaternal associations between 29 SNPs in 12 cell-cycle genes and childhood pre-B acute …